鼻咽癌EBNA3A、3B及3C特异性CTL免疫反应分析  

Analysis of EBNA3A,3B and 3C specific cytotoxic lymphocyte immune response in patients with nasopharyngeal carcinoma

作　　者：刘凯[1,2] 张典刚[1,2] 耿晓涛[1] 胡云辉[1] 王若峥[1,2] 

机构地区：[1]新疆医科大学附属肿瘤医院放疗中心,乌鲁木齐830011 [2]新疆维吾尔自治区肿瘤学重点实验室,乌鲁木齐830011

出　　处：《新疆医科大学学报》2017年第7期891-896,901,共7页Journal of Xinjiang Medical University

基　　金：新疆维吾尔自治区科技计划成果推广项目(201554142)

摘　　要：目的探讨酶联免疫斑点法(ELISPOT)检测鼻咽癌患者放疗前后EBNA3A、3B及3C特异性细胞免疫水平,为免疫治疗靶点的选择及放疗前后免疫状态的判定提供实验室依据。方法选择2014年1月-2015年7月新疆肿瘤医院收治的鼻咽癌初治患者62例为初治组,放疗后6个月组、1年组及1年以上组患者各76例、46例及77例,用ELISPOT法检测EBNA3A、3B及3C特异性CTL水平。结果 (1)初治组汉族和维吾尔族EBNA3C特异性CTL反应频率分别为45.8%和54.2%(χ~2=4.438,P=0.035),分化型和未分化型非角化性鼻咽癌EBNA3C特异性CTL反应频率分别为20.8%和79.2%(χ~2=4.890,P=0.027),EBNA3C特异性CTL反应频率在民族和病理分型比较中差异有统计学意义,在其他临床特征比较中差异无统计学意义;EBNA3C特异性CTL反应强度在临床特征比较中差异无统计学意义,EBNA3A、3B特异性CTL反应频率和强度在年龄、性别、民族、病理分型、T分期、N分期及临床分期各组比较中差异均无统计学意义;(2)初治组与放疗后6月组、1年组及1年以上组在EBNA3A、3B及3C特异性CTL反应频率和强度比较中其差异均无统计学意义。结论 EBNA3C特异性CTL反应可能与病理类型及不同民族免疫状态的判定有关联性,EBNA3A、3B及3C特异性CTL反应可能不能作为评价鼻咽癌放疗前、后判定免疫状态的指标。Objective To explore the level of EBNA3A , EBNA3B and EBNA3C specific cytotoxic immune response in nasopharyngeal carcinoma （NPC） before and after radiotherapy using enzyme - linked immu- nospot assay （ELISPOT） , thereby providing experimental assessment for nasopharyngeal carcinoma dia- gosis, immunotherapy and indicator evaluating the immune status after radiotherapy. Methods 62 NPC patients, 76 NPC 6 months after radiotherapy, 46 NPC 1 year after radiotherapy and 77 NPC over 1 year after radiotherapy were enrolled. The frequency and number of EBNA3A , EBNA3B, and EBNA3C specific cytotoxic immune response were determined using ELISPOT assay. Results （1 ） The frequency of EB- NA3C specific cytotoxic immune reponse were 45.8% and 54.2% in Han ethnicity and Uyghur ethnicity re-spectively （ X^2 =4.438 ,P =0.035） ; The frequency of EBNA3C specific cytotoxic immune response were 20. 8% and 79.2% in differentiated type of non - keratinizing squamous carcinoma and Non -differentiatedtype of non -keratinizing squamous carcinoma respectively （ X^2 =4.890,P =0.027） ; The frequency of EB- NA3C specific cytotoxic immune response was shown to have no significant difference in other clinical fea-tures in NPC without treatment; nor was CTL response in NPC without treatment; The response frequen-cy and cell number of EBNA3A and EBNA3B specific cytotoxic immune response was displayed to have no significance on clinical features in NPC without treatment; （2） The frequency and cell number of EB- NA3A , EBNA3Band EBNA3C specific cytotoxic immune response was shown to have no significant differ-ence between NPC without treatment, NPC 6 months after radiotherapy, NPC 1 year after radiotherapy, NPC over 1 year after radiotherapy. Conclusion EBNA3C specific cytotoxic immune response could be a indicator for the immune status of NPC with different pathology and ethnicity, EBNA3A , EBNA3B and EBNA3C specific cytotoxic immune response could not be used as a

关 键 词：鼻咽癌 EBV T细胞免疫 酶联免疫斑点法 放射治疗 

分 类 号：R739.6[医药卫生—肿瘤]